We noted you are experiencing viewing problems
- 
        
        Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
 - 
        
        Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. - 
        
        No luck yet? More tips for troubleshooting viewing issues
 - 
        
        Contact HST Support access@hstalks.com
 
- 
        Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
 - 
        For additional help, please don't hesitate to contact HST support access@hstalks.com
 
We hope you have enjoyed this limited-length demo
                    
                    This is a limited length demo talk; you may
                    
                      login or
                    
                    review methods of
                    obtaining more access.
                  
                
                
              Printable Handouts
Navigable Slide Index
- Introduction
 - Outline
 - Importance of India in global TB control
 - 8.8 million incident cases of TB in 2010
 - India accounted for 25% of this TB burden
 - No country has more cases of TB than India
 - TB control in India: what has been accomplished?
 - TB control in India is the RNTCP responsibility
 - RNTCP: achievements
 - RNTCP has made the most of existing toolbox
 - TB control in India has been cost-effective
 - Challenges for TB control after DOTS scale-up
 - Very slow decline in TB incidence
 - What factors may explain this?
 - Threat of drug-resistant TB
 - What does "TDR-TB" really indicate?
 - Mismanagement of TB in India
 - RNTCP limited capacity to deal with MDR-TB
 - TB diagnostic practices in the private sector
 - WHO has warned against inaccurate TB tests
 - Widespread use of serological tests for TB
 - Survey: 17 of 22 use these antibody tests
 - Why inaccurate TB tests used in India?
 - Root causes for popularity of serology in India
 - Government of India banned TB serology tests
 - Treatment deviates from international standards
 - TB drugs are very available
 - Impact of TB mismanagement
 - A typical TB patient in India
 - New vision and goals for TB control
 - What is the new vision for TB control?
 - Raising the level of ambition: universal access
 - The RNTCP will pursue the following approaches
 - Universal access via improved, early diagnosis
 - Media campaign
 - Replacing bad with WHO-endorsed tests
 - Engaging to replace serology with WHO-tools
 - Improve notification of TB cases
 - For the new vision to succeed, India needs
 - How can India contribute to global TB control?
 - India's economic growth
 - India's progress in science
 - India's progress in communications
 - Success story with generic drugs and vaccines
 - India is poised to take the lead in TB diagnostics
 - Creating an ecosystem for innovation
 - India can also provide leadership in research
 - India's TB control will impact on global TB control
 - BRICS are now poised to provide new leadership
 - Thank you for listening
 
Topics Covered
- Importance of India in global TB control
 - Burden of TB in India
 - Challenges for TB control in India
 - New vision and goals for TB control in India
 - How can India contribute to global TB control?
 
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Pai, M. (2013, February 28). India: the epicentre of global TB control [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 4, 2025, from https://doi.org/10.69645/RWSA9166.Export Citation (RIS)
Publication History
- Published on February 28, 2013
 
Financial Disclosures
- Dr. Madhukar Pai has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.